Fulan Guan, PhD
DownloadHi-Res Photo
Cards
Appointments
Pharmacology
Primary
Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Titles
Visiting Research Scientist
Contact Info
About
Titles
Associate Research Scientist in Pharmacology
Visiting Research ScientistAppointments
Pharmacology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Guangzhou University of Traditional Chinese Medici (2002)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Fulan Guan's published research.
Publications Timeline
A big-picture view of Fulan Guan's research output by year.
Caroline Helen Johnson, PhD
Jorge Galán, PhD, DVM
Rong Hu, PhD
11Publications
545Citations
Publications
2021
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, Cai W, Cheng W, Liu SH, Cheng P, Cai Y, Rattray NJW, Johnson CH, Chen L, Cheng YC. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports 2021, 11: 13482. PMID: 34188068, PMCID: PMC8242098, DOI: 10.1038/s41598-021-91623-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsM1-like macrophage polarizationMacrophage polarizationIDO activityInterferon gammaInnate immunityTumor microenvironmentTraditional Chinese herbal formulationPD-L1 inductionM1-like macrophagesAdaptive immune responsesM2 macrophage polarizationChinese herbal formulationTumor bearing miceQuality of lifeAnti-tumor activityGastrointestinal symptomsMonocytic MDSCsProlong survivalImmune toleranceAcute inflammationCancer patientsClinical resultsHepatocellular carcinomaImmune responseRadiation therapyProspective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Wu J, Sun B, Hou L, Guan F, Wang L, Cheng P, Scobell S, Cheng YC, Lam W. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. Frontiers In Pharmacology 2021, 11: 615287. PMID: 33716728, PMCID: PMC7947616, DOI: 10.3389/fphar.2020.615287.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTraditional Chinese medicineMaxingshigan decoctionChinese medicineCOVID-19COVID-19 patientsUnique medical needsPublic health measuresNovel coronavirus diseaseBradykinin stormConventional antiviralsHuo-XueAngiotensin systemSystemic inflammationAntiviral effectAntiviral actionIndividual herbsMedical needHealth measuresCoronavirus diseaseUnderlying mechanismOral formulaPathogenesisDiseaseProspective articlesBotanical treatments
2020
Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging
Hou S, He S, Xie J, Li M, Hong M, Guan F, Hu Y, Huang Y, Xu C. Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging. Spectrochimica Acta Part A Molecular And Biomolecular Spectroscopy 2020, 235: 118315. PMID: 32289732, DOI: 10.1016/j.saa.2020.118315.Peer-Reviewed Original ResearchCitations
2018
Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu CH, Liu SH, Cheng YC. Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Frontiers In Pharmacology 2018, 09: 1324. PMID: 30510512, PMCID: PMC6252377, DOI: 10.3389/fphar.2018.01324.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHerbal productsAnimal studiesMechanism actionChinese medicine formulationAnti-tumor activityGastrointestinal symptomsPatients' qualityClinical studiesTherapeutic indexLuciferase reporter cell lineChinese formulationRadiation treatmentCancer treatmentQuality control platformReporter cell lineMedicine formulationCell linesFaster recoveryAnticancer agentsPharmacological usageClinical batchesTreatmentAssaysIrinotecanAppropriate biological assaysExploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles.
Tan Y, Lu C, Jiang M, Zhao N, Li L, Shen S, Guan F, He B, Xiao C, L A, Cheng S, Zu X, Zhang W, Liu X. Exploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles. Journal Of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association Of Traditional Chinese Medicine, Academy Of Traditional Chinese Medicine 2018, 38: 773-780. PMID: 32185996.Peer-Reviewed Original Research
2016
Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70
Wang Y, Lam W, Chen SR, Guan FL, Dutchman GE, Francis S, Baker DC, Cheng YC. Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70. Scientific Reports 2016, 6: 32832. PMID: 27596272, PMCID: PMC5011780, DOI: 10.1038/srep32832.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCyclin D1 translationShock cognate protein 70D1 translationRNA binding motifsHeat shock cognate protein 70Cellular regulatory proteinsNovel regulatory mechanismProtein 70UTR of mRNAsCyclin D1Chaperone activityAllosteric regulationProtein translationRegulatory proteinsElongation stepATP hydrolysisBinding motifRegulatory mechanismsAUUUA motifsMolecular mechanismsCyclin D1 mRNAProcessing complexElevated expressionHsc70MRNAAntibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates
Tsou LK, Lara-Tejero M, RoseFigura J, Zhang ZJ, Wang YC, Yount JS, Lefebre M, Dossa PD, Kato J, Guan F, Lam W, Cheng YC, Galán J, Hang HC. Antibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates. Journal Of The American Chemical Society 2016, 138: 2209-2218. PMID: 26847396, PMCID: PMC4831573, DOI: 10.1021/jacs.5b11575.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVirulence pathwaysType III protein secretionType III secretion system effectorsSpecific plant metabolitesSPI-1 T3SSSecretion system effectorsS. typhimurium invasionSalmonella enterica serovar TyphimuriumSecretion substratesEnterica serovar TyphimuriumTraditional Chinese medicineUnappreciated mechanismPlant metabolitesTyphimurium invasionProtein secretionSerovar TyphimuriumAntibacterial flavonoidsBacterial invasionEpithelial cellsSpecific flavonoidsBacterial growthMedicinal plantsPathwayPotential mechanismsInvasion
2014
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complementary Medicine And Therapies 2014, 14: 490. PMID: 25510341, PMCID: PMC4302098, DOI: 10.1186/1472-6882-14-490.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAnti-Bacterial AgentsAntineoplastic Agents, PhytogenicBacteriaCamptothecinColonic NeoplasmsDrugs, Chinese HerbalFemaleGranulocyte Colony-Stimulating FactorHumansIntestinal MucosaIntestinesIrinotecanMiceNeutrophil InfiltrationPhytotherapyReceptors, G-Protein-CoupledRNA, MessengerTumor Necrosis Factor-alphaWeight LossConceptsBody weight lossAntibiotic treatmentCPT-11Tumor-bearing miceIntestinal bacteriaIntestinal toxicityStem cell markersAntitumor activityAnimal body weight lossCPT-11-treated miceCell markersMRNA expressionTNF-alpha mRNA expressionWeight lossAntibiotic treatment groupCPT-11 treatmentCytokines G-CSFProgenitor/stem cell markersLactobacillus/EnterococcusIntestinal damageInflammatory processIntestinal bacterial profilesTreatment groupsPCNA stainingTumor allografts
2013
PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues
Kong A, Lam, Bussom S, Jiang Z, Zhang W, Guan F, Liu S, Cheng Y. PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues. 2013, 549-562. DOI: 10.1201/b15323-38.Peer-Reviewed Original Research
2011
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Medical Genomics 2011, 4: 38. PMID: 21569348, PMCID: PMC3117677, DOI: 10.1186/1755-8794-4-38.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAnimalsCamptothecinCell Line, TumorCell ProliferationColonic NeoplasmsDrug InteractionsDrugs, Chinese HerbalFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHep G2 CellsHumansImmunityImmunohistochemistryInflammationIrinotecanLiverMacrophagesMedicine, Chinese TraditionalMiceOrgan SizePolymerase Chain ReactionReproducibility of ResultsRNA, MessengerSignal TransductionSpleenTumor MicroenvironmentConceptsCPT-11Subcutaneous colon 38 tumoursChinese medicinePro-inflammatory pathwaysPre-clinical modelsColon 38 tumorsBDF-1 miceTraditional Chinese medicineRNA microarray technologyTumor rejectionInflammatory processPharmacodynamic propertiesAntitumor effectsSide effectsTCM formulaAnimal studiesPrevalent inductionTherapeutic effectivenessPHY906Tumor tissueTumor microenvironmentGood manufacturing practicesTumorsDistinct alterationsTissue-specific responses
Links & Media
News
Get In Touch
Contacts
Email